Tucotuzumab celmoleukin

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Tucotuzumab celmoleukin ^?
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	EpCAM
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	339986-90-2^Y
ATC code	None
KEGG	D09027^Y
Chemical data
Formula	C₇₈₁₂H₁₂₁₂₄N₂₀₄₄O₂₄₀₈S₆₀
Mol. mass	175.1 kDa
Y (what is this?) (verify)

Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin).^[1]^[2]^[3]

This drug was developed by EMD Pharmaceuticals.

[edit] References

^ Statement On A Nonproprietary Name Adopted By The Usan Council - Tucotuzumab Celmoleukin, American Medical Association.
^ ClinicalTrials.gov
^ National Cancer Institute: Definition of tucotuzumab celmoleukin

Monoclonal antibodies for tumors

Tumor ("-t(u[m])-")

Human ("-tumu-")	Adecatumumab Belimumab Cixutumumab Conatumumab Daratumumab Drozitumab Figitumumab Ganitumab Glembatumumab vedotin Intetumumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Narnatumab Necitumumab Ofatumumab Olaratumab Panitumumab Pritumumab Radretumab Rilotumumab Robatumumab Teprotumumab Votumumab Zalutumumab "-melu-" (melanoma): Flanvotumab

Mouse ("-tumo-")	Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab CC49 Detumomab Ibritumomab tiuxetan Minretumomab Mitumomab Moxetumomab pasudotox Naptumomab estafenatox Nofetumomab merpentan Pemtumomab^† Pintumomab Racotumomab Satumomab pendetide Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor): Abagovomab Igovomab Oregovomab "-pro-" (prostate tumor): Capromab pendetide "-colo-" (colonic tumor): Edrecolomab Nacolomab tafenatox

Chimeric ("-tuxi-")	Amatuximab Bavituximab Brentuximab vedotin Cetuximab Ensituximab Girentuximab Indatuximab ravtansine Rituximab Siltuximab Ublituximab "-mexi-" (melanoma): Ecromeximab

Humanized ("-tuzu-")	Afutuzumab Alemtuzumab Bevacizumab Bivatuzumab mertansine Cantuzumab mertansine Cantuzumab ravtansine Citatuzumab bogatox Clivatuzumab tetraxetan Dacetuzumab Dalotuzumab Elotuzumab^† Etaracizumab Farletuzumab Ficlatuzumab Gemtuzumab ozogamicin Inotuzumab ozogamicin Labetuzumab Lintuzumab Lorvotuzumab mertansine Matuzumab^§ Milatuzumab Nimotuzumab Onartuzumab Oportuzumab monatox Pertuzumab Sibrotuzumab Tacatuzumab tetraxetan Tigatuzumab Trastuzumab Tucotuzumab celmoleukin Veltuzumab

Rat/mouse hybrid ("-tumaxo-")	Catumaxomab Ertumaxomab